Novo Nordisk (NVO)
(Delayed Data from NYSE)
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $117.96 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $117.96 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth A Momentum B VGM
Zacks News
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
by Zacks Equity Research
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX
by Andrew Rocco
The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical level.
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
by Zacks Equity Research
Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
Amgen Stock Rises Almost 20% in 6 Months: Buy, Sell or Hold?
by Kinjel Shah
AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.
Viking Surges 342% in the Past Year: How Should You Play the Stock?
by Sundeep Ganoria
VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.
Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day.
Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound
by Zacks Equity Research
LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
by Zacks Equity Research
VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, Uber, Spok Holdings and Willis Lease Finance
by Zacks Equity Research
Microsoft, Novo Nordisk, Uber, Spok Holdings and Willis Lease Finance are included in this Analyst Blog.
Top Research Reports for Microsoft, Novo Nordisk & Uber
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), Novo Nordisk A/S (NVO) and Uber Technologies, Inc. (UBER), as well as two micro-cap stocks Spok Holdings, Inc. (SPOK) and Willis Lease Finance Corp. (WLFC).
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
by Zacks Equity Research
Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.
Zacks Investment Ideas feature highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly
by Zacks Equity Research
Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly have been highlighted in this Investment Ideas article.
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
by Andrew Rocco
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?
by Kinjel Shah
After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.
Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
by Kinjel Shah
Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
by Zacks Equity Research
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.